Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (341-350 of 440) with videos related to

Pageof 44
Sort By:
Biorxiv : the Preprint Server for Biology|April 22, 2024
Multi-Niche Human Bone Marrow On-A-Chip for Studying the Interactions of Adoptive CAR-T Cell Therapies with Multiple MyelomaDelta Ghoshal, Ingrid Petersen, Rachel Ringquist, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 25, 2017
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple MyelomaErik H van Beers, Martin H van Vliet, Rowan Kuiper, et al.
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
The Lancet. Haematology|September 16, 2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a studyKevin R Kelly, Sikander Ailawadhi, David S Siegel, et al.
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.
The Lancet. Haematology|October 19, 2016
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trialJesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
The Journal of Biological Chemistry|May 5, 2017
HMG-CoA synthase 1 is a synthetic lethal partner of BRAF<sup>V600E</sup> in human cancersLiang Zhao, Jun Fan, Siyuan Xia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Pageof 44

Showing results (341-350 of 440) with videos related to

Sort By:
Pageof 44
Biorxiv : the Preprint Server for Biology|April 22, 2024
Multi-Niche Human Bone Marrow On-A-Chip for Studying the Interactions of Adoptive CAR-T Cell Therapies with Multiple MyelomaDelta Ghoshal, Ingrid Petersen, Rachel Ringquist, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 25, 2017
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple MyelomaErik H van Beers, Martin H van Vliet, Rowan Kuiper, et al.
The Lancet. Oncology|September 1, 2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trialShaji K Kumar, Susanna J Jacobus, Adam D Cohen, et al.
The Lancet. Haematology|September 16, 2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a studyKevin R Kelly, Sikander Ailawadhi, David S Siegel, et al.
Blood|July 27, 2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaDavid S Siegel, Thomas Martin, Michael Wang, et al.
Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.
The Lancet. Haematology|October 19, 2016
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trialJesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
The Journal of Biological Chemistry|May 5, 2017
HMG-CoA synthase 1 is a synthetic lethal partner of BRAF<sup>V600E</sup> in human cancersLiang Zhao, Jun Fan, Siyuan Xia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationAntonio Palumbo, S Vincent Rajkumar, Jesus F San Miguel, et al.
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Pageof 44